ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
Official Title  Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors
Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor.

PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor.

Detailed Description

OBJECTIVES:

  • Compare the effect of interval-compressed vs standard chemotherapy in terms of event-free survival and overall survival in patients with newly diagnosed, localized Ewing's sarcoma or peripheral primitive neuroectodermal tumor.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (under 18 years vs 18 years and over) and location of primary disease (pelvic vs nonpelvic). Patients are randomized to 1 of 2 treatment arms for induction and continuation therapy.

  • Induction therapy (weeks 1-12):

    • Arm I: Patients receive alternating courses of chemotherapy consisting of vincristine IV on day 1, doxorubicin IV continuously over 48 hours on days 1 and 2, and cyclophosphamide IV over 1 hour on day 1 for courses 1 and 3 and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 for courses 2 and 4. Beginning 24 hours after the last dose of chemotherapy for each course, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Treatment continues every 3 weeks for 4 courses.
    • Arm II: Patients receive alternating courses of chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide as in arm I for courses 1, 3, and 5 and ifosfamide and etoposide as in arm I for courses 2, 4, and 6. Patients also receive G-CSF as in arm I. Treatment continues every 2 weeks for 6 courses.

After completion of induction therapy, patients in both arms receive local control treatment to the primary tumor. Patients receive continuation chemotherapy after surgery or concurrently with radiotherapy.

  • Continuation therapy:

    • Arm I (weeks 13-42): Patients receive additional alternating courses of chemotherapy as in arm I of induction therapy with the exception of vincristine and cyclophosphamide alone for courses 7 and/or 11 and/or 13. Patients also receive G-CSF as in induction therapy. Treatment continues every 3 weeks for 10 courses.
    • Arm II (weeks 13-29): Patients receive additional alternating courses of chemotherapy as in arm II of induction therapy with the exception of vincristine and cyclophosphamide alone for courses 9 and/or 11 and/or 13. Patients also receive G-CSF as in induction therapy. Treatment continues every 2 weeks for 8 courses.

Patients are followed every 3 months for 4 years and then every 6 months for 1 year.

PROJECTED ACCRUAL: Approximately 528 patients will be accrued for this study within 4-5 years.

Study Phase Phase III
Study Type  Interventional
Study Design  Treatment, Randomized, Active Control
Primary Outcome Measure  Event-free survival [ Designated as safety issue: No ]
Secondary Outcome Measure 
Condition  Sarcoma
Intervention  Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: filgrastim
Drug: ifosfamide
Drug: vincristine
Procedure: adjuvant therapy
Procedure: brachytherapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Procedure: radiation therapy
MEDLINE PMIDs
Links Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Active, not recruiting
Enrollment 
Start Date  May 2001
Completion Date
Eligibility Criteria 

DISEASE CHARACTERISTICS:

  • Histologically confirmed localized Ewing's sarcoma or peripheral primitive neuroectodermal tumor (PNET) of the bone or soft tissues

    • Diagnostic biopsy of primary tumor within 30 days of study
  • Paraspinal or bony skull tumors of extradural origin allowed

    • No intradural soft tissue tumors
  • Askin's tumor of the chest wall allowed

    • Chest wall tumors with ipsilateral pleural effusions or ipsilateral pleural-based secondary tumor nodules allowed
    • No contralateral pleural effusions
  • No metastatic disease or distant node involvement

    • One pulmonary or pleural nodule greater than 1 cm in diameter OR more than 1 nodule greater than 0.5 cm in diameter are considered pulmonary metastasis
    • Solitary lung nodules of 0.5-1 cm OR multiple nodules of 0.3-0.5 cm allowed unless biopsy positive for tumor
  • Light microscopic appearance (hematoxylin and eosin stained) consistent with Ewing's sarcoma or peripheral PNET
  • No immunohistochemical or ultrastructural evidence of rhabdomyosarcoma
  • No esthesioneuroblastoma
  • Clinically or pathologically involved regional lymph nodes allowed
  • No CNS involvement

PATIENT CHARACTERISTICS:

Age:

  • 50 and under at diagnosis

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Bilirubin no greater than 1.5 mg/dL

Renal:

  • Creatinine normal for age
  • Creatinine clearance or isotope glomerular filtration rate at least 75 mL/min

Cardiovascular:

  • Shortening fraction at least 28% by echocardiography OR
  • Ejection fraction at least 55% by radionuclide angiogram

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No other prior malignancy except skin cancer diagnosed at least 5 years ago and currently in remission

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior immunotherapy for skin cancer
  • No concurrent sargramostim (GM-CSF)
  • No concurrent pegfilgrastim

Chemotherapy:

  • No prior chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior radiotherapy

Surgery:

  • Prior complete or partial excision of primary tumor allowed
Gender Both
Ages up to 50 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States,   Australia,   Canada,   Netherlands,   New Zealand,   Puerto Rico,   Switzerland
Administrative Information Fields
NCT ID  NCT00006734
Organization ID CDR0000068323
Secondary IDs †† COG-AEWS0031, CCG-A7983, SWOG-COG-AEWS0031
Study Sponsor  Children's Oncology Group
Collaborators †† National Cancer Institute (NCI)
Southwest Oncology Group
Investigators 
Study Chair:     Richard B. Womer, MD     Children's Hospital of Philadelphia    
Investigator:     Karen H. Albritton, MD     Dana-Farber Cancer Institute    
Information Provided By National Cancer Institute (NCI)
Verification Date October 2005
First Received Date  December 6, 2000
Last Updated Date May 23, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers